RMD — ResMed Inc. stock price, charts and financials

QT33ResMed Inc.

ResMed Inc. (NYSE: RMD) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
219.46
+7.52+3.55%
RMDQT33ResMed Inc.·NYSE
219.46+3.55%
News
Up 3.5% — ResMed Q4 Earnings Call Highlights (marketbeat.com).
Medium confidence
TA
Loading chart...
Signal & projected range
Insider open-market saleHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
IndexS&P 500P/E20.84EPS (ttm)10.17Insider Own0.95%Shs Outstand145.06MPerf Week0.46%
Market Cap30.74BForward P/E15.98EPS next Y13.26Insider Trans-3.19%Shs Float144.16MPerf Month1.67%
Enterprise Value30.10BPEG3.21EPS next Q-Inst Own-Short Float9.39%Perf Quarter2.44%
Income1.51BP/S5.44EPS this Y16.62%Inst Trans-Short Ratio8.74Perf Half Y-20.64%
Sales5.65BP/B4.71EPS next Y9.97%ROA16.99%Short Interest13.54MPerf YTD-12.01%
Book/sh-P/C9.83EPS next 5Y10.23%ROE23.88%52W High304.21 -27.86%Perf Year-24.43%
Cash/sh-P/FCF10.64EPS past 3/5Y21.52% 17.37%ROIC19.11%52W Low186.66 17.57%Perf 3Y-4.60%
Dividend Est.2.40 (1.09%)EV/EBITDA15.95Sales past 3/5Y12.88% 11.72%Gross Margin61.06%Volatility3.55% 3.00%Perf 5Y-22.02%
Dividend TTM2.40 (1.09%)EV/Sales5.32EPS Y/Y TTM49.42%Oper. Margin33.48%ATR (14)7.66Perf 10Y222.59%
Dividend Ex-DateMay 14, 2026Quick Ratio2.42Sales Y/Y TTM18.21%Profit Margin26.94%RSI (14)53.74Recom2.74
Dividend Gr. 3/5Y9.53% 7.70%Current Ratio3.10EPS Q/Q17.70%SMA203.14%Beta0.74Target Price239.67
Payout40.19%Debt/Eq0.13Sales Q/Q10.76%SMA505.78%Rel Volume2.46Prev Close211.94
Employees10,600LT Debt/Eq0.14EarningsOct 29SMA200-8.15%Avg Volume1.53MPrice219.46
IPO DateJun 02, 1995Option/ShortYes / YesEPS/Sales Surpr.2.32% 0.81%Net Debt/EBITDA-0.34Volume3,773,863Change3.55%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-07-26ReiteratedRobert W. Baird$217$213
Aug-07-26ReiteratedKeyBancOverweight$260$255
Jul-21-26ReiteratedUBSBuy$345$300
Jul-16-26ReiteratedRBC CapitalOutperform$276$234
Jul-15-26ReiteratedMizuhoOutperform$265$220
Jul-13-26DowngradeCitigroupBuyNeutral
Jul-10-26ReiteratedJefferiesHold$240$225
Jul-08-26ReiteratedRBC CapitalOutperform$314$276
Jul-08-26ReiteratedWells FargoEqual Weight$280$225
Jun-22-26ReiteratedKeybancOverweight$290$266
Latest News
Aug-09-26
Aug-09-2612:05AM
Aug-07-26
Aug-06-26
Aug-05-26
Aug-04-26
Aug-03-26
Jul-31-26
Jul-30-26
Jul-28-26
Company

ResMed Inc. is a leading global medical technology enterprise engaged in the creation, production, distribution, and marketing of healthcare devices and connected digital solutions. The company operates through two primary segments: Sleep and Respiratory Care, and Software as a Service. Its extensive product range addresses a variety of respiratory disorders, encompassing advanced medical and consumer technologies, ventilation devices, diagnostic equipment, mask systems for both clinical and personal use, headgear, and related accessories, alongside dental devices. ResMed also provides sophisticated cloud-based informatics to enhance patient management and operational efficiency. Notable software offerings in its respiratory portfolio include AirView, for remote device monitoring and setting adjustments; myAir, a personalized application designed to support sleep apnea patients with education and troubleshooting for better engagement and adherence; and U-Sleep, a compliance tracking platform for home medical equipment providers. Complementing these are connectivity modules and Propeller solutions. Furthermore, ResMed offers a robust suite of out-of-hospital software. This includes Brightree, a business management platform for various home care service providers (e.g., HME, pharmacy, infusion, orthotics, prosthetics); MatrixCare, providing care management for senior living, skilled nursing, and hospice organizations; and HEALTHCAREfirst, which supplies electronic health records, billing, coding services, and analytics for home health and hospice agencies. ResMed distributes its offerings primarily to sleep clinics, home healthcare dealers, and hospitals via a global network of distributors and a direct sales force, serving approximately 140 countries. Founded in 1989, the company's headquarters are located in San Diego, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2026
6/30/2026
FY 2025
6/30/2025
FY 2024
6/30/2024
FY 2023
6/30/2023
FY 2022
6/30/2022
FY 2021
6/30/2021
FY 2020
6/30/2020
FY 2019
6/30/2019
Total Revenue5,6545,6535,146
Cost of Goods Sold Incl. D&A2,2012,2022,091
Gross Profit3,4523,4523,055
Selling, General and Administrative Excl. Other1,1081,108991
Research and Development378378331
Other Operating Expense797948
Operating Income1,8941,8871,685
Interest Expense505013
Unusual Expense
Non-Operating Income (Expense)77835
Net Income Before Taxes1,9191,9191,678
Income Taxes397396277
Consolidated Net Income1,5241,5231,401
Net Income From Continuing Operations1,49001,401
Net Income1,5241,5231,401
EPS (Recurring)10.170.009.55
EPS (Basic, Before Extraordinaries)10.170.009.55
EPS (Diluted)10.130.009.51
EBITDA1,8861,8871,913
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio21.6627.13
Price To Sales Ratio7.37
Gross Margin61.0561.0659.37
Operating Margin33.5033.3832.74
Net Margin26.9526.9427.23
Shares Outstanding00147
Market Capitalization37,926
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$310.37$274.32$238.28$202.23$166.18 Close Price0.00M0.97M1.95M2.92M3.89MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
FARRELL PETER CDirectorAug 05 '26Sale225.008,0001,800,00052,773Aug 06
Farrell Michael J.Chairman and CEOJul 07 '26Option Exercise146.344,991730,383471,214Jul 09
Farrell Michael J.Chairman and CEOJul 07 '26Sale218.554,9911,090,771466,223Jul 09
Farrell Michael J.Chairman and CEOJun 08 '26Option Exercise146.344,991730,383471,214Jun 09
Farrell Michael J.Chairman and CEOJun 08 '26Sale193.964,991968,064466,256Jun 09
Farrell Michael J.Chairman and CEOMay 07 '26Option Exercise146.344,991730,383471,214May 11
Farrell Michael J.Chairman and CEOMay 07 '26Sale207.824,9911,037,233466,223May 11
Farrell Michael J.Chairman and CEOApr 07 '26Option Exercise146.344,991730,383471,214Apr 09
Farrell Michael J.Chairman and CEOApr 07 '26Sale225.504,9911,125,486466,223Apr 09
Sandercock BrettChief Financial OfficerApr 01 '26Sale224.311,000224,31083,495Apr 03
FARRELL PETER CDirectorApr 01 '26Sale225.002,000450,00060,773Apr 02
Farrell Michael J.Chairman and CEOMar 09 '26Option Exercise146.344,991730,383471,214Mar 11
Farrell Michael J.Chairman and CEOMar 09 '26Sale251.034,9911,252,902466,223Mar 11
FARRELL PETER CDirectorMar 04 '26Sale260.222,000520,44062,773Mar 05
Sandercock BrettChief Financial OfficerMar 02 '26Sale254.301,000254,30084,495Mar 03
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.